Infectious Disease Research Institute (IDRI) Expands Board, Adding Additional International Expertise With Dr Massimo Radaelli
Dr. Radaelli is Chairman, President & CEO of Noventia Pharma, a company which operates in Southern Europe, he founded in 2009. Noventia Pharma offers a product portfolio of pharmaceuticals with a specialized business dedicated to treatments of rare and neglected diseases. Dr. Radaelli also serves as Executive Chairman of Bioakos Pharma, a specialty pharmaceutical company based in Florence, Italy, and focused in the areas of dermatology, gynecology and pediatrics. Prior to founding Noventia Pharma, Dr. Radaelli served as President and Chief Executive Officer of Dompe International SA, where he was responsible for the company’s global sales and export activities. Dr. Radaelli received a degree in pharmaceutical sciences and a Ph.D. in Clinical Pharmacology from the University of Milan and an Executive Master of Business from Bocconi University of Milan.
“Massimo’s wealth of knowledge in the international biotech and pharmaceutical industries makes him a terrific addition to IDRI’s board,” said Stewart Parker, CEO of IDRI. “With our focus on developing products to solve global health challenges caused by infectious diseases, IDRI will benefit from Massimo’s extensive experience in developing key industry partnerships and launching products worldwide.”
In addition to being a member of IDRI’s Board of Directors, Dr. Radaelli serves on a number of corporate boards in Europe and in US, including Massachusetts-based ARIAD Pharmaceuticals, Inc., which is developing breakthrough medicines for cancer patients with difficult-to-treat malignancies, such as chronic myeloid leukemia and non-small cell lung cancer.
About IDRI
The Infectious Disease Research Institute (IDRI) is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of poverty. By integrating capabilities, including early stage drug discovery, preclinical testing, manufacturing and clinical trials, IDRI strives to create an efficient pathway bringing scientific innovation from the laboratory to the people who need it most.
For more information, please visit www.idri.org.
MEDIA CONTACTS:
Erik Iverson: 206.518.6280
Lee Schoentrup: 206.518.6290
media@idri.org